Long-term persistence of the immune response to antipneumococcal vaccines after Allo-SCT: 10-year follow-up of the EBMT-IDWP01 trial

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Bone Marrow Transplantation

• Publication date

  2015-04-13

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/bmt.2015.42PMID 25867652
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.

  2014cited by this paper
• 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.

  2014cited by this paper
• Antibody persistence ten years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adults

  2011cited by this paper
• Immune response to the 23-valent polysaccharide pneumococcal vaccine after the 7-valent conjugate vaccine in allogeneic stem cell transplant recipients: results from the EBMT IDWP01 trial.

  2010cited by this paper
• Safety and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine Compared to Those of a 7-Valent Pneumococcal Conjugate Vaccine Given as a Three-Dose Series with Routine Vaccines in Healthy Infants and Toddlers

  2010cited by this paper
• Relationship between IgG titers and opsonocytophagocytic activity of anti-pneumococcal antibodies after immunization with the 7-valent conjugate vaccine in allogeneic stem cell transplant

  2010cited by this paper
• Vaccination of hematopoietic cell transplant recipients

  2009cited by this paper
• Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation.

  2009cited by this paper
• Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory.

  2008cited by this paper
• Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue?

  2007cited by this paper
• Streptococcus pneumoniae Infections in 47 Hematopoietic Stem Cell Transplantation Recipients: Clinical Characteristics of Infections and Vaccine-Breakthrough Infections, 1989-2005

  2007cited by this paper
• Immunogenicity of Pneumococcal Vaccine in Renal Transplant Recipients—Three Year Follow‐up of a Randomized Trial

  2007cited by this paper
• A randomized, double-blind trial of pneumococcal vaccination in adult allogeneic stem cell transplant donors and recipients.

  2007cited by this paper
• Pneumococcal conjugate vaccine provides early protective antibody responses in children after related and unrelated allogeneic hematopoietic stem cell transplantation.

  2007cited by this paper
• Vaccination of Hematopoietic Cell Transplant Recipients

  2007cited by this paper
• Donor immunization with pneumococcal conjugate vaccine and early protective antibody responses following allogeneic hematopoietic cell transplantation.

  2003cited by this paper
• Early and late invasive pneumococcal infection following stem cell transplantation: a European Bone Marrow Transplantation survey

  2002cited by this paper
• Pneumococcal Type 22F Polysaccharide Absorption Improves the Specificity of a Pneumococcal-Polysaccharide Enzyme-Linked Immunosorbent Assay

  2001cited by this paper
• A comparison of multiple regimens of pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine and pneumococcal polysaccharide vaccine in toddlers.

  2000cited by this paper
• Immunogenicity of Haemophilus influenzae type b conjugate vaccine in allogeneic bone marrow recipients.

  1992cited by this paper
• Titers of antibody to pneumococci in allogeneic bone marrow transplant recipients before and after vaccination with pneumococcal vaccine.

  1986cited by this paper

• Preventing pneumococcal infections in patients with hematological malignancies: a review of evidence and recommendations based on modified Delphi consensus

  2025cites this paper
• Revaccination with pneumococcal conjugate vaccine five years after primary immunization improves immunity in patients with chronic lymphocytic leukemia

  2025cites this paper
• Vaccination of Adults With Cancer: ASCO Guideline

  2024cites this paper
• Antibody responses after sequential vaccination with PCV13 and PPSV23 in patients with moderate to severe plaque psoriasis under immunosuppressive therapy

  2024cites this paper
• A comprehensive overview of pneumococcal vaccination recommendations for adults in South Africa, 2022

  2022cites this paper
• Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study

  2021cites this paper
• A Review of Vaccinations in Adult Patients with Secondary Immunodeficiency

  2021cites this paper
• Coronavirus disease 2019 vaccination in transplant recipients

  2021cites this paper
• Vaccination Schedules

  2020cites this paper
• Clinical Effectiveness of Conjugate Pneumococcal Vaccination In Hematopoietic Stem Cell Transplant Recipients.

  2020cites this paper
• Humoral immune response to tick-borne encephalitis vaccination in allogeneic blood and marrow graft recipients

  2020cites this paper
• Measuring the cellular memory B cell response after vaccination in patients after allogeneic stem cell transplantation

  2020cites this paper
• Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7).

  2019cites this paper
• Infection prevention by vaccinations in immunocompromised patients

  2019cites this paper
• ANTIPNEUMOCOCCAL SEROPROTECTION YEARS AFTER VACCINATION IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS.

  2019cites this paper
• Long-term pneumococcal vaccine immunogenicity following allogeneic hematopoietic stem cell transplantation.

  2019cites this paper
• Vaccination of the Stem Cell Transplant Recipient and the Hematologic Malignancy Patient.

  2019cites this paper
• A survey of infectious diseases and vaccination uptake in long‐term hematopoietic stem cell transplant survivors in Australia

  2019cites this paper
• Serologic response to pneumococcal vaccination in children experiencing recurrent invasive pneumococcal disease

  2018cites this paper
• Antibody persistence after pneumococcal conjugate vaccination in patients with chronic lymphocytic leukemia

  2018cites this paper
• The immunogenicity of 7‐valent pneumococcal conjugate vaccine (PCV7) in adult bone marrow transplant patients

  2018cites this paper
• 69 – Vaccination of Immunocompromised Hosts

  2018cites this paper
• National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report.

  2017cites this paper
• Bacterial bloodstream infections in the allogeneic hematopoietic cell transplant patient: new considerations for a persistent nemesis

  2017cites this paper
• An aberrant NOTCH2-BCR signaling axis in B cells from patients with chronic GVHD.

  2017cites this paper
• Vaccination of allogeneic hematopoietic stem cell transplant recipients—what should be considered?

  2017cites this paper
• Measuring Immune Response to Commonly Used Vaccinations in Adult Recipients of Allogeneic Hematopoietic Cell Transplantation.

  2017cites this paper
• Vaccinations in patients with hematological malignancies.

  2016cites this paper
• Vaccination of Transplant Recipients

  2016cites this paper